Biological and clinical markers in colorectal cancer: State of the art

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 2, 2010, Pages 422-431

  Cappellani, Alessandro ^a   Di Vita, Maria ^a   Zanghi, Antonio ^a   Veroux, Pierfrancesco ^a   Cavallaro, Andrea ^b   Lo Menzo, Emanuele ^c   Cacopardo, Bruno ^b   Canzonieri, Vincenzo ^d   Murabito, Paolo ^a   Tirelli, Umberto ^d   Berretta, Massimiliano ^d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF MARYLAND   (United States)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Colorectal cancer; Prognosis; Review; Screening; Target therapy; Tumor markers

Indexed keywords

ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; TUMOR MARKER;

BLOOD; CANCER INVASION; CELL PROLIFERATION; CHEMISTRY; COLORECTAL TUMOR; EARLY DIAGNOSIS; FECES; HUMAN; METABOLISM; METHODOLOGY; REVIEW; URINE;

ANGIOGENESIS INDUCING AGENTS; CELL ADHESION MOLECULES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; HUMANS; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957311638     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s75     Document Type: Article

References (67)

1. Parkin D. M., F. Bray, J. Ferlay and P. Pisani: Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94(2), 153-6 (2001)] (Pubitemid 32911406)
2. Benson V. S., J. Patnick, A. K. Davies, M. R. Nadel, R. A. Smith and W. S. Atkin: Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer, 122(6), 1357-67 (2008) (Pubitemid 351287237)
3. Ries L.A.G., D. Melbert, M. Krapcho, A. Mariotto, B.A. Miller, E.J. Feuer, L. Clegg, M.J. Horner, N. Howlader, M.P. Eisner, M. Reichman, B.K. Edwards (eds) SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD,
4. Winawer S. J., A. G. Zauber, M. J. O'Brien, M. N. Ho, L. Gottlieb, S. S. Sternberg, J. D. Waye, J. Bond, M. Schapiro, E. T. Stewart and et al.: Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med, 328(13), 901-6 (1993) (Pubitemid 23086641)
5. Atkin W.: Options for screening for colorectal cancer. Scand J Gastroenterol Suppl, (237), 13-6 (2003) (Pubitemid 36609872)
6. Faivre J., V. Dancourt, C. Lejeune, M. A. Tazi, J. Lamour, D. Gerard, F. Dassonville and C. Bonithon-Kopp: Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology, 126(7), 1674-80 (2004) (Pubitemid 38736331)
7. Hardcastle. J. D., J. O. Chamberlain, M. H. Robinson, S. M. Moss, S. S. Amar, T. W. Balfour, P. D. James and C. M. Mangham: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet, 348(9040), 1472-7 (1996) (Pubitemid 26400242)
8. Kronborg O., C. Fenger, J. Olsen, O. D. Jorgensen and O. Sondergaard: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet, 348(9040), 1467-71 (1996) (Pubitemid 26400241)
9. Mandel J. S., J. H. Bond, T. R. Church, D. C. Snover, G. M. Bradley, L. M. Schuman and F. Ederer: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med, 328(19), 1365-71 (1993) (Pubitemid 23131388)
10. Heresbach D., S. Manfredi, N. D'Halluin P, J. F. Bretagne and B. Branger: Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol, 18(4), 427-33 (2006)
11. Kahi C. J, T. F. Imperiale, B. E. Juliar and D. K. Rex: Effect of Screening Colonoscopy on Colorectal Cancer Incidence and Mortality. Clin Gastroenterol Hepatol, 7(7):770-5; (2009)
12. Jorgensen O. D., O. Kronborg and C. Fenger: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut, 50(1), 29-32 (2002) (Pubitemid 34028299)
13. Cole S. R. and G. P. Young: Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust, 175(4), 195-8 (2001) (Pubitemid 32791339)
14. van Rossum L. G., A. F. van Rijn, R. J. Laheij, M. G. van Oijen, P. Fockens, H. H. van Krieken, A. L. Verbeek, J. B. Jansen and E. Dekker: Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology, 135(1), 82-90 (2008) (Pubitemid 351899018)
15. Denters M. J., M. Deutekom, P. Fockens, P. M. Bossuyt and E. Dekker: Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands. BMC Gastroenterol, 9, 28 (2009)
16. Duffy M. J., A. van Dalen, C. Haglund, L. Hansson, E. Holinski-Feder, R. Klapdor, R. Lamerz, P. Peltomaki, C. Sturgeon and O. Topolcan: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer, 43(9), 1348-60 (2007) (Pubitemid 46874070)
17. Haug U. and H. Brenner: New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int J Cancer, 117(2), 169-76 (2005) (Pubitemid 41377434)
18. Imperiale TF, Ransohoff DF, Itzkowitz S.H., Turnbull BA, Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med, 351(26), 2704-14 (2004) (Pubitemid 39665324)
19. Ouyang D. L., J. J. Chen, R. H. Getzenberg and R. E. Schoen: Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol, 100(6), 1393-403 (2005) (Pubitemid 40904368)
20. D. A. Ahlquist, D. J. Sargent, C. L. Loprinzi, T. R. Levin, D. K. Rex, D. J. Ahnen, K. Knigge, M. P. Lance, L. J. Burgart, S. R. Hamilton, J. E. Allison, M. J. Lawson, M. E. Devens, J. J. Harrington and S. L. Hillman: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med, 149(7), 441-50, W81 (2008)
21. D. Whitney, J. Skoletsky, K. Moore, K. Boynton, L. Kann, R. Brand, S. Syngal, M. Lawson and A. Shuber: Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn, 6(4), 386-95 (2004) (Pubitemid 39517408)
22. L. Kann, J. Han, D. Ahlquist, T. Levin, D. Rex, D. Whitney, S. Markowitz and A. Shuber: Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia. Clin Chem, 52(12), 2299-302 (2006) (Pubitemid 44925007)
23. D. C. Chung: Stool DNA testing and colon cancer prevention: another step forward. Ann Intern Med, 149(7), 509-10 (2008)
24. T. Nagasaka, A. Goel, N. Matsubara and N. Tanaka: Detection of fecal DNA methylation for colorectal neoplasia: does it lead to an optimal screening test? Acta Med Okayama, 60(5), 249-56 (2006) (Pubitemid 46142092)
25. Wang D. R. and D. Tang: Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol, 14(4), 524-31 (2008) (Pubitemid 351320817)
26. Muller M., M. Meyer, T. Schilling, E. Ulsperger, T. Lehnert, H. Zentgraf, W. Stremmel, M. Volkmann and P. R. Galle: Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol, 29(4), 973-80 (2006)
27. Lu H., V. Goodell and M. L. Disis: Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res, 7(4), 1388-94 (2008)
28. Lu H., V. Goodell and M. L. Disis: Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets, 11(2), 235-44 (2007) (Pubitemid 46188816)
29. Xu W. H., Y. D. Chen, Y. Hu, J. K. Yu, X. G. Wu, T. J. Jiang, S. Zheng and S. Z. Zhang: Preoperatively molecular staging with CM10 Protein Chip and SELDI-TOF-MS for colorectal cancer patients. J Zhejiang Univ Sci B, 7(3), 235-40 (2006)
30. Yamashita K. and M. Watanabe. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci., 100 (2): 195-9.(2009)
31. Melle C., G. Ernst, B. Schimmel, A. Bleul, H. Thieme, R. Kaufmann, H. Mothes, U. Settmacher, U. Claussen, K. J. Halbhuber and F. Von Eggeling: Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology, 129(1), 66-73 (2005) (Pubitemid 41002043)
32. Albrethsen J., R. Bogebo, S. Gammeltoft, J. Olsen, B. Winther and H. Raskov: Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer, 5, 8 (2005)
33. Habermann J. K., U. J. Roblick, B. T. Luke, D. A. Prieto, W. J. Finlay, V. N. Podust, J. M. Roman, E. Oevermann, T. Schiedeck, N. Homann, M. Duchrow, T. P. Conrads, T. D. Veenstra, S. K. Burt, H. P. Bruch, G. Auer and T. Ried: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology, 131(4), 1020-9; quiz 1284 (2006)
34. Hiramatsu K., K. Takahashi, T. Yamaguchi, H. Matsumoto, H. Miyamoto, S. Tanaka, C. Tanaka, Y. Tamamori, M. Imajo, M. Kawaguchi, M. Toi, T. Mori and M. Kawakita: N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early. and late-stage colorectal and breast cancers. Clin Cancer Res, 11(8), 2986-90 (2005) (Pubitemid 40525203)
35. Rowley P. T.: Inherited susceptibility to colorectal cancer. Annu Rev Med, 56, 539-54 (2005)
36. Fearnhead N. S., J. L. Wilding and W. F. Bodmer: Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull, 64, 27-43 (2002) (Pubitemid 35238577)
37. Sampson J. R., S. Jones, S. Dolwani and J. P. Cheadle: MutYH (MYH) and colorectal cancer. Biochem Soc Trans, 33 (Pt 4), 679-83 (2005) (Pubitemid 41160838)
38. National Comprehensive Cancer Network Clinical practice Guidelines in Oncology, colorectal cancer screening, version 1. 2006.
39. Giardiello F. M., J. D. Brensinger and G. M. Petersen: AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology, 121(1), 198-213 (2001) (Pubitemid 32591530)
40. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology, 121(1), 195-7 (2001)
41. Vasen H. F., J. P. Mecklin, P. M. Khan and H. T. Lynch: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) Dis Colon Rectum, 34(5), 424-5 (1991)
42. Boland C. R., S. N. Thibodeau, S. R. Hamilton, D. Sidransky, J. R. Eshleman, R. W. Burt, S. J. Meltzer, M. A. Rodriguez-Bigas, R. Fodde, G. N. Ranzani and S. Srivastava: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res, 58(22), 5248-57 (1998) (Pubitemid 28521189)
43. Locker G. Y, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes and R. C. Bast, Jr.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24(33), 5313-27 (2006) (Pubitemid 46631379)
44. Chen C. C., S. H. Yang, J. K. Lin, T. C. Lin, W. S. Chen, J. K. Jiang, H. S. Wang and S. C. Chang: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res, 124(2), 169-74 (2005)
45. Kim J. C., K. H. Lee, C. S. Yu, H. C. Kim, J. R. Kim, H. M. Chang, J. H. Kim, J. S. Kim and T. W. Kim: The clinicopathological significance of inferior mesenteric lymph node metastasis in colorectal cancer. Eur J Surg Oncol, 30(3), 271-9 (2004) (Pubitemid 38425644)
46. Weissenberger C., G. Von Plehn, F. Otto, A. Barke, F. Momm and M. Geissler: Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer Res, 25(3A), 1787-93 (2005) (Pubitemid 40896804)
47. Park Y. J., K. J. Park, J. G. Park, K. U. Lee, K. J. Choe and J. P. Kim: Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg, 23(7), 721-6 (1999) (Pubitemid 29314417)
48. Park Y. J., E. G. Youk, H. S. Choi, S. U. Han, K. J. Park, K. U. Lee, K. J. Choe and J. G. Park: Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Colorectal Dis, 14(2), 101-6 (1999) (Pubitemid 29295192)
49. Wu Z. Y., J. Wan, G. Zhao, L. Peng, J. L. Du, Y. Yao, Q. F. Liu and H. H. Lin: Risk factors for local recurrence of middle and lower rectal carcinoma after curative resection. World J Gastroenterol, 14(30), 4805-9 (2008)
50. Wang, J. K. Lin, T. J. Chiou, J. H. Liu, F. S. Fan, C. C. Yen, T. C. Lin, J. K. Jiang, S. H. Yang, H. S. Wang and P. M. Chen: Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol, 30(1), 12-6 (2000)
51. Takagawa R., S. Fujii, M. Ohta, Y. Nagano, C. Kunisaki, S. Yamagishi, S. Osada, Y. Ichikawa and H. Shimada: Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol, 15(12), 3433-9 (2008)
52. Sorbye H. and O. Dahl: Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol, 21(23), 4466-7 (2003)
53. Nomura T. and N. Katunuma: Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest, 52(1-2), 1-9 (2005)
54. Kuester D., H. Lippert, A. Roessner and S. Krueger: The cathepsin family and their role in colorectal cancer. Pathol Res Pract, 204(7), 491-500 (2008)
55. Forsti A., H. Lei, B. Tavelin, K. Enquist, R. Palmqvist, A. Altieri, G. Hallmans, K. Hemminki and P. Lenner: Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann Oncol, 18(12), 1990-4 (2007) (Pubitemid 350286237)
56. Moehler M., C. Frings, A. Mueller, I. Gockel, C. C. Schimanski, S. Biesterfeld, P. R. Galle and M. H. Holtmann: VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol, 14(26), 4156-67 (2008)
57. Hawinkels L. J., K. Zuidwijk, H. W. Verspaget, E. S. de Jonge-Muller, W. van Duijn, V. Ferreira, R. D. Fontijn, G. David, D. W. Hommes, C. B. Lamers and C. F. Sier: VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer, 44(13), 1904-13 (2008)
58. Maltese P, E. Canestrari, A. Ruzzo, F. Graziano, A. Falcone, F. Loupakis, G. Tonini, D. Santini and M. Magnani: VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis, 24(2), 165-70 (2009)
59. Haraguchi M., K. Komuta, T. Ueda, A. Akashi, S. Minami, J. Furui and T. Kanematsu: Prognostic significance of the serum thymidine phosphorylase levels in venous blood drainage specimens in patients with colorectal cancer. Hepatogastroenterology, 55(82-83), 418-21 (2008) (Pubitemid 351741473)
60. Italiano A., M. C. Saint-Paul, F. X. Caroli-Bosc, E. Francois, A. Bourgeon, D. Benchimol, J. Gugenheim and J. F. Michiels: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol, 16(9), 1503-7 (2005) (Pubitemid 41222423)
61. de Castro-Carpeño J, Belda-Iniesta C, Casado Sáenz E, Hernández Agudo E, Feliu Batlle J, González Barón M. EGFR and colon cancer: a clinical view. Clin Transl Oncol. Jan; 10(1):6-13.(2008) Review.
62. Karapetis C. S., S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, T. J. Price, L. Shepherd, H. J. Au, C. Langer, M. J. Moore and J. R. Zalcberg: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 359(17), 1757-65 (2008)
63. Allegra C. J., J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton and R. L. Schilsky: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol, 27(12), 2091-6 (2009)
64. Lugli A., I. Zlobec, P. Minoo, K. Baker, L. Tornillo, L. Terracciano and J. R. Jass: Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology, 50(4), 453-64 (2007) (Pubitemid 46328181)
65. Mohr A., C. Buneker, R. P. Gough and R. M. Zwacka: MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene, 27(6), 763-74 (2008) (Pubitemid 351186311)
66. Rudmik R. and A. M. Magliocco: Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol, 92(4), 347-59 (2005) (Pubitemid 41779295)
67. Xu X. M., C. He, X. T. Hu and B. L. Fang: Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29. World J Gastroenterol, 9(5), 965-9 (2003) (Pubitemid 36681662)